PROT# 3129K2-1105-WW: An Open-Label, Phase 1 Study of R-CVP or R-GDP in Combination with Inotuzumab Ozogamicin in Subjects with CD22-Positive Non-Hodgkin's Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date7/15/107/15/13

Funding

  • ICON Clinical Research, LLC (3129K2-1105-WW)
  • Pfizer Inc. (3129K2-1105-WW)